Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004401 · ClinicalTrials.gov registry record · NA
Study of Human Botulism Immunoglobulin in Infants With Botulism
A NA study of Botulism and Infant Botulism, sponsored by California Department of Health Services.
- Completed
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT00004401 is a NA study of Botulism and Infant Botulism that has completed, run by California Department of Health Services. The registered enrollment target is 120 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00004401, a NA study of Botulism and Infant Botulism, has completed, sponsored by California Department of Health Services.
- COMPLETED
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
OBJECTIVES: I. Determine the safety of human botulism immune globulin (BIG) in patients with infant botulism by monitoring side effects (e.g., rash, fever, hypotension, and anaphylaxis). II. Assess the efficacy of BIG in these patients by monitoring disease severity, incidence of complications (respiratory arrest, aspiration, pneumonia, etc.), and length of hospital stay.
Conditions Studied
Interventions
- DRUG botulism immune globulin
Study Locations (1)
California
- California Department of Health Services - Berkeley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 1998-01 |
| Est. Completion | 1998-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004401
The ClinicalTrials.gov registry entry for NCT00004401 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is California Department of Health Services, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Botulism appearing as the primary indexed condition, and to 1 intervention - of which botulism immune globulin is the first listed.
NCT00004401 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00004401 about?
NCT00004401 is a clinical study titled "Study of Human Botulism Immunoglobulin in Infants With Botulism". OBJECTIVES: I. Determine the safety of human botulism immune globulin (BIG) in patients with infant botulism by monitoring side effects (e.g., rash, fever, hypotension, and anaphylaxis). II. Assess the efficacy of BIG in these patients by monitoring disease severity, incidence of complications (res...
What is the current status of trial NCT00004401?
This trial is currently completed. It is a NA study. The enrollment target is 120 participants. The study started on 1998-01. Estimated completion is 1998-06.
What conditions does trial NCT00004401 study?
This clinical trial studies the following conditions: Botulism, Infant Botulism.
What interventions are being tested in trial NCT00004401?
The interventions under investigation include: botulism immune globulin (DRUG).
Who is sponsoring clinical trial NCT00004401?
This trial is sponsored by California Department of Health Services, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00004401 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Botulism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.